Corvus Pharmaceuticals SG&A Expense (TTM) Analysis

Corvus Pharmaceuticals Inc (CRVS)

1.81 +0.03 (+1.69%) USD | NASDAQ | Jul 05, 15:52

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2015. Upgrade now.

Date	Value
March 31, 2024	7.079M
December 31, 2023	6.881M
September 30, 2023	6.815M
June 30, 2023	7.328M
March 31, 2023	7.764M
December 31, 2022	8.097M
September 30, 2022	8.533M
June 30, 2022	8.481M
March 31, 2022	8.575M
December 31, 2021	9.515M
September 30, 2021	10.18M
June 30, 2021	11.35M
March 31, 2021	12.08M
December 31, 2020	11.93M
September 30, 2020	11.76M
June 30, 2020	11.05M
March 31, 2020	11.10M

Date	Value
December 31, 2019	10.88M
September 30, 2019	11.14M
June 30, 2019	11.39M
March 31, 2019	10.98M
December 31, 2018	10.64M
September 30, 2018	10.36M
June 30, 2018	9.796M
March 31, 2018	10.04M
December 31, 2017	10.22M
September 30, 2017	9.837M
June 30, 2017	10.40M
March 31, 2017	9.313M
December 31, 2016	7.622M
September 30, 2016	6.699M
June 30, 2016	4.536M
March 31, 2016	3.157M
December 31, 2015	2.418M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

6.815M

Minimum

Sep 2023

12.08M

Maximum

Mar 2021

9.502M

Average

9.515M

Median

Dec 2021

SG&A Expense (TTM) Benchmarks